1.Beta-Thymosins.(Ann NYAcad Sci.2007 Sep;1112:21-37.)
2.Thymosin alphal:a promising molecule for important clinical applications.(Med Arh. 2009;63(1):48-50.)
3. A randomized, placebo-controlled, single and multiple dose study of intravenousthymosin beta4 in healthy volunteers. (Ann NY Acad Sci. 2010Apr;1194:223-229.)
4. Thymosin beta4 and corneal wound healing: visions of the future. (Ann NY Acad Sci.2010Apr;1194:190-198.)
5.From lab to bedside: emerging clinical applications of thymosin alpha 1.(Expert OpinBiol Ther.2009May;9(5):593-608.)
6. Thymosin beta4 regulates migration of colon cancer cells by a pathway involvinginteraction with Ku80.(Ann NY Acad Sci.2010 Apr;1194:60-71.)
7.Preclinical studies with IRx-2 and thymosin alphal in combination therapy. (Ann NYAcad Sci.2010;1194:162-168.)
8.Advances in thymosin beta10 research: differential expression, molecular mechanisms,and clinical implications in cancer and other conditions.(Cancer Invest.2009Dec;27(10):1016-1022.)
9. Thymosin beta4 in multiple myeloma: friend or foe. (Ann NY Acad Sci.2010Apr;1194:125-9.)
10. Prothymosin alpha and cell death mode switch, a novel target for the prevention ofcerebral ischemia-induced damage.(Pharmacol Ther.2009Sep;123(3):323-333.)
11.Thymosin beta4 is cardioprotective after myocardial infarction.
12.(Ann NY Acad Sci.2007Sep;1112:161-70.)
13. Thymosin beta4: a key factor for protective effects of eEPCs in14.acute and chronic ischemia. (Ann NYAcad Sci.2010Apr;1194:105-11.)15. Prothymosin alpha plays a key role in cell death mode-switch, a16.new concept for neuroprotective mechanisms in stroke. (Naunyn17.Schmiedebergs Arch Pharmacol.2008;377:315-323.)